Navigation Links
LTCPA Study Quantifying Unused Medicare Part D Drugs in Skilled Nursing Facilities Published in The Consultant Pharmacist

WASHINGTON, Sept. 7, 2011 /PRNewswire-USNewswire/ -- The Long Term Care Pharmacy Alliance's (LTCPA) recent study, "Measurement of Unused Medication in Medicare D Residents in Skilled Nursing Facilities," has been published in the September 2011 issue of The Consultant Pharmacist, the official peer-reviewed journal of the American Society of Consultant Pharmacists. This is the first published, peer-reviewed study to measure the quantity and the value of unused solid oral dosage from prescription drugs among Medicare Part D–covered residents in skilled nursing facilities.  The study was based upon actual dispensed and returned prescription data provided to the authors by long-term care pharmacies, and its data and methodology have undergone a rigorous peer-review.  

The study highlights several important findings:

  • The cost of unused Part D drug products dispensed to skilled nursing facility residents that could feasibly be reduced to shorter fill times – identified as brand and generic oral solid prescriptions – amounts to about 2.9% of total dispensed value of all prescriptions, or $125 million annually.
  • Based on the value of the unused drugs, moving to shorter fills via "short cycle dispensing" will very likely result in higher costs to the Medicare program. Shorter fills will result in more dispensed prescriptions and more dispensing fees charged to Medicare Part D prescription plans, overwhelming any potential savings.

The study, conducted by Managed Solutions, LLC and originally released by LTCPA in January 2011, supports pharmacists' contention that the "short cycle dispensing" provision inserted within the Patient Protection and Affordable Care Act (PPACA) is likely to create greater health care costs rather than savings. The intent of the provision was to reduce costs associated with medications unused by Part D-covered skilled nursing facility residents by moving from traditional 30-day fills to shorter fill times such as biweekly, weekly or daily. Debate has circulated around this provision and subsequent rule-making, as robust data quantifying the amount and costs associated with unused pharmaceuticals in the long term care space were not available. The study fills this gap in data and demonstrates that the costs associated with increasing the number of monthly dispensings are likely to outweigh any cost savings from reducing unused drugs.

To read the published study, click here.

The Long Term Care Pharmacy Alliance (LTCPA) advocates for the interests of the long term care (LTC) pharmacy community - a community that provides a critical component to the daily care of individuals living in LTC settings. LTCPA provides a national, unified voice on major issues including LTC pharmacy costs, specialized nursing facility pharmacy services and the Medicare Part D prescription drug benefit.  LTCPA membership is comprised of three national LTC pharmacy providers, Managed Health Care Associates (MHA), Omnicare and PharMerica that together serve 1.8 million Medicare Part D beneficiaries, or ninety percent of all LTC facility residents.

SOURCE Long Term Care Pharmacy Alliance (LTCPA)
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Long Term Care Pharmacy Alliance Concerned with Proposed CMS Rule; New Study Confirms LTCPA Position
2. Boehringer Ingelheim and Lilly to Feature Type 2 Diabetes Research in Presentations at the 47th Annual Meeting of the European Association for the Study of Diabetes
3. Auxilium Pharmaceuticals, Inc. Announces Positive Top-Line Results from XIAFLEX® Multi-Cord Study
4. NIH-Funded Study Demonstrates That Patients Receiving New CPR Devices (ResQPOD® and ResQPump™) and Cooling Have Improved Long-Term Brain Function Following Cardiac Arrest
5. Study Uncovers Key Success Factors and Common Failure Points for Launching New Metabolic Products in Todays Competitive Healthcare Market
6. Study Explores Utilization Trends for Prostate Cancer Treatments
7. Pearl Therapeutics Announces Positive Results for Phase 2b Dose-Ranging Study of Formoterol MDI
8. Kuros Completes Patient Recruitment in its European Clinical Study With KUR-023, its Novel Dural Sealant Product Candidate
9. New Study Shows Modified Citrus Pectin Activates Powerful Immune Responses
10. Ultragenyx Initiates Phase 1 Clinical Study of UX001 in Hereditary Inclusion Body Myopathy (HIBM), a Rare Muscle Wasting Disease
11. Comparative Study Confirms Enox Biopharmas Antimicrobial Superiority to Commercially Available Silver Coated Catheters
Post Your Comments:
(Date:11/25/2015)... -- Allergan plc (NYSE: AGN ) today announced that ... York State Attorney General,s Office to end the ... statutes with the Attorney General over the decision of Forest ... selling the now generic version of memantine immediate release tablets.  ... released its counterclaims against New York , ...
(Date:11/25/2015)... -- Allergan plc (NYSE: AGN ), a ... start-up  biotechnology company focused on the development of ... by the F-Prime Biomedical Research Initiative (FBRI), today ... collaboration to support the discovery and development of ... Obsessive Compulsive disorders (OCD). ...
(Date:11/25/2015)... 2015 --> ... devices was valued at $11,171.1 million in 2014, and ... 5.7% during 2015 - 2022. The global market is ... of diabetes. In addition, the increase in obese population ... to the growth of the market. Furthermore, technological advancements ...
Breaking Medicine Technology:
(Date:11/26/2015)... CA (PRWEB) , ... November 26, 2015 , ... ... a new set of retro-fused, self-animating trailer titles with ProTrailer: Vintage. This newly ... options. These classically-influenced trailer titles work with any font, giving users limitless opportunities ...
(Date:11/25/2015)... ... November 25, 2015 , ... ... the perfect dish and pleasing the palates of attendees is of the utmost ... dish to a seasonal get-together, give these recipes a try this holiday season. ...
(Date:11/25/2015)... ... November 26, 2015 , ... Ministers, senior government and ... Pan African Centres of Excellence, and public R&D institutions, civil societies and other ... of the 5th African Network for Drugs and Diagnostics Innovation, ANDI, Stakeholders Meeting. ...
(Date:11/25/2015)... ... November 25, 2015 , ... Dental professionals who would ... OH , are invited to attend Dr. Mark Iacobelli’s Advanced Implant Mentoring (AIM) CE ... Cleveland, OH. , As the co-founders of Advanced Implant Mentoring (AIM), Dr. Iacobelli ...
(Date:11/25/2015)... ... ... Smiles by Stevens is pleased to announce the addition of Botox® for the ... of the benefits of Botox® in the treatment of moderate facial wrinkling, few have ... pain as a result of Jaw Tension, TMJ (temporo-mandibular joint) disorder, and Bruxism (the ...
Breaking Medicine News(10 mins):